Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1221-1240 of 1,694 trials

Myotonia Treatment: Mexiletine PR vs. Mexiletine IR

We are comparing two forms of mexiletine to see which one is safer and more effective for adults with non-dystrophic myotonias. This study aims to improve treatment options for conditions like myotonia congenita and paramyotonia congenita.

Myotonic DystrophyNon-Dystrophic Myotonias6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Seizures in Developmental and Epileptic Encephalopathy: Bexicaserin (LP352)

We are studying the safety and effectiveness of a new medication, bexicaserin, for treating seizures in children and adults with developmental and epileptic encephalopathy. This research aims to understand how well it works for managing their condition.

Developmental and Epileptic Encephalopathies1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Rheumatoid Arthritis: AP1189 with Methotrexate

We are studying a new oral medication, AP1189, for people with early rheumatoid arthritis who haven't received other treatments. The goal is to see if it works better with methotrexate than methotrexate alone.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementRheumatology

Multiple Myeloma: Isatuximab with Novel Agents

We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Belumosudil and Dexamethasone

We are studying a new combination of treatments for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if this combination improves treatment outcomes.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Evorpacept and Dexamethasone

We are studying a new treatment combination for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if it improves treatment responses compared to existing options.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Cancer Pain Management: Paracetamol with Opioids

We are studying whether stopping paracetamol affects pain control in patients using strong opioids for cancer-related pain. We also want to see if this change impacts side effects and overall patient satisfaction.

Metastatic Cancer≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineOncology

Nephrogenic Diabetes Insipidus: Amiloride Treatment Study

We are investigating whether amiloride can help patients with nephrogenic diabetes insipidus caused by lithium treatment for bipolar disorder. The study looks at its effects on urine concentration, thirst, and quality of life.

Bipolar Disorder with Lithium Treatment>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNephrologyPsychiatry

Septic Shock: Ivabradine for Heart Rate Control

We are studying whether Ivabradine can help control heart rate and improve survival in patients with septic shock. This trial compares the medication to a placebo to assess its effectiveness.

Septic Shock>2 yearsConfirmation phase (III)Standard MedicinesCardiologyInfectious DiseasesInternal Medicine

Mitapivat for Children with Pyruvate Kinase Deficiency

We are studying whether Mitapivat can help increase hemoglobin levels in children with Pyruvate Kinase Deficiency who do not receive regular blood transfusions. This trial compares the treatment to a placebo to assess its effectiveness.

Pyruvate Kinase Deficiency Anemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteHematologyPediatrics

Blood Cancers: AZD0486 Treatment Study

We are investigating whether AZD0486, alone or with other cancer drugs, is safe and effective for adults with certain blood cancers. This includes conditions like chronic lymphocytic leukemia and large B-cell lymphoma.

Mantle Cell LymphomaLarge B-Cell LymphomaChronic Lymphocytic LeukaemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Alzheimer's Disease: Donepezil vs. Non-Drug Treatment

We are studying whether daily donepezil can improve thinking skills in people with Alzheimer's compared to usual non-drug care. We will also look at its effects on quality of life and other clinical measures.

Alzheimer's Disease6-12 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesNeurology

Right Heart Failure: Dapagliflozin Study

We are investigating whether adding dapagliflozin to standard care helps patients with chronic right heart failure more than standard care alone. This study aims to improve treatment options for these patients.

Chronic Right Heart Failure6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Apalutamide with Surgery

We are studying if adding apalutamide to standard hormone therapy helps men with high-risk prostate cancer after surgery. The goal is to see if this combination improves cancer control compared to hormone therapy alone.

Metastatic Prostate Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Primary Plasma Cell Leukemia: ARI0002h CAR-T Cell Therapy

We are studying a new CAR-T cell treatment for patients newly diagnosed with primary plasma cell leukemia. The trial aims to evaluate its safety, effectiveness, and impact on quality of life.

Plasma Cell Leukaemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Metoprolol for Heart Health in Duchenne Muscular Dystrophy

We are studying whether metoprolol can help prevent heart issues in boys aged 8-17 with Duchenne Muscular Dystrophy. This trial will compare its effects to a placebo alongside standard heart care.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyNeurology

Marfan Syndrome: Valsartan for Aortic Health

We are studying whether valsartan can slow down aortic root dilatation in children and young adults with Marfan syndrome. The trial will measure changes in aortic size and related health outcomes.

Marfan SyndromeLoeys-Dietz SyndromeEhlers-Danlos Syndrome>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Heart Failure: Sertraline for Anxiety and Depression

We are studying whether sertraline can help reduce anxiety and depression symptoms in heart failure patients. The trial also looks at its effects on heart health and overall well-being.

Heart Failure with Preserved Ejection Fraction and Anxiety>2 yearsConfirmation phase (III)Investigational MedicinesCardiologyPsychiatry

Acute Ischemic Stroke: Mechanical Thrombectomy Study

We are studying whether adding a mechanical procedure to standard treatment helps patients with acute ischemic stroke due to large vessel blockage. The trial also examines safety and quality of life for participants.

Malignant Ischemic Stroke>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Myelodysplastic Syndromes: Oral ASTX030 vs. Subcutaneous Azacitidine

We are studying a new oral treatment for patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. The trial aims to evaluate its safety and how it compares to the standard subcutaneous treatment.

Chronic Myelomonocytic LeukaemiaAcute Myeloid LeukaemiaMyelodysplastic Syndrome>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesHematology